|
|
- In vitro evaluation of fenfluramine and norfenfluramine as victims of drug
interactions
Authors:
Parthena Martin; Maciej Czerwiński,
Pallavi B. Limaye,
Seema Muranjan,
Brian W. Ogilvie,
Steven Smith,
Brooks Boyd
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-22T09:30:19-07:00
DOI: 10.1002/prp2.958
Issue No: Vol. 10, No. 3 (2022)
- In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely
to act as perpetrators of drug interactions
Authors:
Parthena Martin; Maciej Czerwiński,
Pallavi B. Limaye,
Brian W. Ogilvie,
Steven Smith,
Brooks Boyd
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-22T09:30:03-07:00
DOI: 10.1002/prp2.959
Issue No: Vol. 10, No. 3 (2022)
- Association of income and educational levels with adherence to direct oral
anticoagulant therapy in patients with incident atrial fibrillation: A
Finnish nationwide cohort study
Authors:
Konsta Teppo; Jussi Jaakkola,
Fausto Biancari,
Olli Halminen,
Miika Linna,
Jari Haukka,
Jukka Putaala,
Paula Tiili,
Ossi Lehtonen,
Mikko Niemi,
Pirjo Mustonen,
Janne Kinnunen,
Juha Hartikainen,
K. E. Juhani Airaksinen,
Mika Lehto
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-22T09:10:22-07:00
DOI: 10.1002/prp2.961
Issue No: Vol. 10, No. 3 (2022)
- Hypothesis: Amelioration of obesity¯induced cognitive dysfunction via a
lorcaserin¯“betahistine combination treatment
Authors:
Ike C. dela Peña; Johnny D. Figueroa,
Weiâ€Xing Shi
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-22T09:04:58-07:00
DOI: 10.1002/prp2.947
Issue No: Vol. 10, No. 3 (2022)
- Hearing loss: The final frontier of pharmacology
Authors:
Alan C. Foster; Bonnie E. Jacques,
Fabrice Piu
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-22T09:04:12-07:00
DOI: 10.1002/prp2.970
Issue No: Vol. 10, No. 3 (2022)
- Pharmacokinetics, pharmacodynamics, and safety of verinurad with and
without allopurinol in healthy Asian, Chinese, and non¯Asian
participants
Authors:
Susanne Johansson; David Han,
Thomas Hunt,
Karin Björck,
Delia Florica,
Michael Gillen,
Jesse Hall,
Fredrik Erlandsson
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-20T07:29:15-07:00
DOI: 10.1002/prp2.929
Issue No: Vol. 10, No. 3 (2022)
- The efficacy and safety of fingolimod plus standardized treatment versus
standardized treatment alone for acute ischemic stroke: A systematic
review and meta¯analysis
Authors:
Peng Bai; Runxiu Zhu,
Ping Wang,
Feng Jiang,
Jin Zhen,
Yuan Yao,
Chenhui Zhao,
Zihong Liang,
Meiling Wang,
Bin Liu,
Min Li,
Na Li,
Jun Yuan
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-18T12:00:00-07:00
DOI: 10.1002/prp2.972
Issue No: Vol. 10, No. 3 (2022)
- Atezolizumab plus carboplatin and nab¯paclitaxel versus carboplatin and
nab¯paclitaxel as treatments for Chinese, treatment¯naí¯ve, stage
IV, non¯squamous, non¯small¯cell lung cancer patients: A
retrospective analysis
Authors:
Yingkai Chen; Shizhou Kang,
Ming Yan
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-14T11:59:49-07:00
DOI: 10.1002/prp2.941
Issue No: Vol. 10, No. 3 (2022)
- Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting
multiple oncogenic pathways
Authors:
Haofeng Lu; Lin Zhou,
Hongping Zuo,
Wenjin Le,
Jianfei Hu,
Tiequan Zhang,
Mi Li,
Yufeng Yuan
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-14T11:50:02-07:00
DOI: 10.1002/prp2.954
Issue No: Vol. 10, No. 3 (2022)
- An open‐label randomized study of the relative absorption of
gastro‐resistant risedronate taken fasted or with food versus
immediate‐release risedronate
Authors:
Diane Kleinermans; Andrew Joyson,
Heather Wray
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-08T01:54:45-07:00
DOI: 10.1002/prp2.957
Issue No: Vol. 10, No. 3 (2022)
- Corrigendum
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-05T11:45:01-07:00
DOI: 10.1002/prp2.948
Issue No: Vol. 10, No. 3 (2022)
- Patient safety in home care: A multicenter cross‐sectional study about
medication errors and medication management of nurses
Authors:
Sandra Strube‐Lahmann; Ursula Müller‐Werdan,
Jürgen Klingelhöfer‐Noe,
Ralf Suhr,
Nils Axel Lahmann
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-04T12:04:42-07:00
DOI: 10.1002/prp2.953
Issue No: Vol. 10, No. 3 (2022)
- Inhibitory role of recombinant neorudin on canine coronary artery
thrombosis
Authors:
Yu‐bin Liu; Xing‐chen Zhou,
Yun Liu,
Lin Zhang,
Ying Zhou,
Xiao Xu,
Can Zheng,
Zhuan‐you Zhao,
Chu‐tse Wu,
Ji‐de Jin
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-05-03T10:55:11-07:00
DOI: 10.1002/prp2.956
Issue No: Vol. 10, No. 3 (2022)
- Dynamic muscle paralytic effects of a novel botulinum toxin A free of
neurotoxin‐associated proteins
Authors:
Wu‐chao Liu; Jun‐hui Su,
Ya Feng,
Xue‐rui Xiang,
Li‐zhen Pan,
Ying Liu,
Lin Ma,
Zhi‐yu Nie,
Xue‐ping Zhang,
Ling‐jing Jin
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-28T09:19:51-07:00
DOI: 10.1002/prp2.955
Issue No: Vol. 10, No. 3 (2022)
- Docosahexaenoic acid and eicosapentaenoic acid strongly inhibit prostanoid
TP receptor‐dependent contractions of guinea pig gastric fundus smooth
muscle
Authors:
Keyue Xu; Miyuki Shimizu,
Chika Murai,
Miki Fujisawa,
Daichi Ito,
Noboru Saitoh,
Yutaka Nakagome,
Mio Yamashita,
Azusa Murata,
Shunya Oikawa,
Guanghan Ou,
Kento Yoshioka,
Keisuke Obara,
Yoshio Tanaka
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-24T09:35:09-07:00
DOI: 10.1002/prp2.952
Issue No: Vol. 10, No. 3 (2022)
- Untargeted metabolomics identifies the potential role of monocarboxylate
transporter 6 (MCT6/SLC16A5) in lipid and amino acid metabolism pathways
Authors:
Tianjing Ren; Robert S. Jones,
Marilyn E. Morris
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-24T09:24:19-07:00
DOI: 10.1002/prp2.944
Issue No: Vol. 10, No. 3 (2022)
- Impact of the mouse estrus cycle on cannabinoid receptor agonist‐induced
molecular and behavioral outcomes
Authors:
Hye Ji J. Kim; Ayat Zagzoog,
Tallan Black,
Sarah L. Baccetto,
Udoka C. Ezeaka,
Robert B. Laprairie
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-24T09:14:41-07:00
DOI: 10.1002/prp2.950
Issue No: Vol. 10, No. 3 (2022)
- Assessment of porphyrogenicity of drugs and chemicals in selected hepatic
cell culture models through a fluorescence‐based screening assay
Authors:
Christopher D. Ma; Cynthia G. Van Horn,
Meimei Wan,
Colin Bishop,
Herbert L. Bonkovsky
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-21T03:39:39-07:00
DOI: 10.1002/prp2.951
Issue No: Vol. 10, No. 3 (2022)
- Inhibition of epigenetic reader proteins by apabetalone counters
inflammation in activated innate immune cells from Fabry disease patients
receiving enzyme replacement therapy
Authors:
Li Fu; Sylwia Wasiak,
Laura M. Tsujikawa,
Brooke D. Rakai,
Stephanie C. Stotz,
Norman C. W. Wong,
Jan O. Johansson,
Michael Sweeney,
Connie M. Mohan,
Aneal Khan,
Ewelina Kulikowski
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-13T08:18:07-07:00
DOI: 10.1002/prp2.949
Issue No: Vol. 10, No. 3 (2022)
- Issue Information
Abstract: Pharmacology Research & Perspectives, Volume 10, Issue 3, June 2022.
PubDate: 2022-04-12T09:29:53-07:00
DOI: 10.1002/prp2.804
Issue No: Vol. 10, No. 3 (2022)
|
Open Access journal
